Case report: JAK inhibition as promising treatment option of fatal RVCLS due to <i>TREX1</i> mutation (pVAL235Glyfs<sup>*</sup>6).

Ufer, Friederike; Ziegler, Susanne M; Altfeld, Marcus; Friese, Manuel A

Case report: JAK inhibition as promising treatment option of fatal RVCLS due to TREX1 mutation (pVAL235Glyfs^*6).

Ufer, Friederike; Ziegler, Susanne M; Altfeld, Marcus; Friese, Manuel A.

Afiliação

Ufer F; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ziegler SM; Department of Virus Immunology, Leibniz Institute for Virology, Hamburg, Germany.
Altfeld M; Department of Virus Immunology, Leibniz Institute for Virology, Hamburg, Germany.
Friese MA; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Front Neurol ; 14: 1118369, 2023.

Article em En | MEDLINE | ID: mdl-36895907

Palavras-chave

CXCL10; JAK inhibition; TREX1; brain vascular disorder; hereditary autoinflammatory diseases; immunosuppression

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article